A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models

Journal of Immunology

Volumn 187, Issue 10, 2011, Pages 4935-4946

  Nakashima, Hideyuki ^a   Terabe, Masaki ^b   Berzofsky, Jay A ^b   Husain, Syed R ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CD3 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOTOXIN; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; BREAST SARCOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T CELL DEPLETION; TUMOR IMMUNITY;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CANCER VACCINES; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXOTOXINS; FEMALE; GENE TARGETING; IMMUNOTHERAPY; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; SARCOMA, EXPERIMENTAL; VACCINES, DNA; VIRULENCE FACTORS;

EID: 81455135913     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102095     Document Type: Article

References (46)

1. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. (Pubitemid 39273730)
2. Rice, J., C. H. Ottensmeier, and F. K. Stevenson. 2008. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8: 108-120. (Pubitemid 351161331)
3. Cheever, M. A., and C. S. Higano. 2011. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17: 3520-3526.
4. Emens, L. A., and E. M. Jaffee. 2005. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65: 8059-8064. (Pubitemid 41330564)
5. Gulley, J. L., R. A. Madan, and P. M. Arlen. 2007. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25 (Suppl. 2): B89-B96. (Pubitemid 47488548)
6. Pastan, I., R. Hassan, D. J. FitzGerald, and R. J. Kreitman. 2007. Immunotoxin treatment of cancer. Annu. Rev. Med. 58: 221-237. (Pubitemid 46706511)
7. Puri, R. K., P. Leland, N. I. Obiri, S. R. Husain, R. J. Kreitman, G. P. Haas, I. Pastan, and W. Debinski. 1996. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87: 4333-4339. (Pubitemid 26155030)
8. Pastan, I., R. Hassan, D. J. Fitzgerald, and R. J. Kreitman. 2006. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6: 559-565. (Pubitemid 43980544)
9. Kunwar, S., M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, J. H. Sampson, Z. Ram, P. H. Gutin, R. D. Gibbons, et al. Cintredekin Besudotox Intraparenchymal Study Group. 2007. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25: 837-844. (Pubitemid 350002884)
10. Romero, P., M. Pittet, V. Dutoit, A. Zippelius, D. Liénard, F. Lejeune, P. Guillaume, D. Rimoldi, D. Valmori, D. E. Speiser, and J.-C. Cerottini. 2002. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine 20 (Suppl. 4): A2-A7. (Pubitemid 35449401)
11. Husain, S. R., N. I. Obiri, P. Gill, T. Zheng, I. Pastan, W. Debinski, and R. K. Puri. 1997. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3: 151-156. (Pubitemid 27107288)
12. Husain, S. R., B. H. Joshi, and R. K. Puri. 2001. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92: 168-175. (Pubitemid 32225365)
13. Joshi, B. H., G. E. Plautz, and R. K. Puri. 2000. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60: 1168-1172. (Pubitemid 30151975)
14. Caput, D., P. Laurent, M. Kaghad, J. M. Lelias, S. Lefort, N. Vita, and P. Ferrara. 1996. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J. Biol. Chem. 271: 16921-16926. (Pubitemid 26239062)
15. Kawakami, M., K. Kawakami, S. Takahashi, M. Abe, and R. K. Puri. 2004. Analysis of interleukin-13 receptor a2 expression in human pediatric brain tumors. Cancer 101: 1036-1042. (Pubitemid 39100438)
16. Kawakami, K., and R. K. Puri. 2003. Interleukin-13 and cancer. In Interleukin-13. F. Brombacher, ed. Landes Bioscience, Austin, TX, p. 65-78.
17. Fujisawa, T., B. Joshi, A. Nakajima, and R. K. Puri. 2009. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 69: 8678-8685.
18. Kawakami, K., M. Terabe, M. Kawakami, J. A. Berzofsky, and R. K. Puri. 2006. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res. 66: 4434-4442.
19. Nakashima, H., T. Fujisawa, S. R. Husain, and R. K. Puri. 2010. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J. Transl. Med. 8: 116.
20. Herber, D. L., S. Nagaraj, J. Y. Djeu, and D. I. Gabrilovich. 2007. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res. 67: 5067-5069. (Pubitemid 46997239)
21. Frey, A. B. 2006. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116: 2587-2590. (Pubitemid 44511621)
22. Zea, A. H., P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65: 3044-3048. (Pubitemid 40524582)
23. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777-2790. (Pubitemid 44511641)
24. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
25. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131. (Pubitemid 43165981)
26. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero. 2009. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58: 49-59.
27. Suzuki, E., V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda. 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721. (Pubitemid 41339014)
28. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
29. Joshi, B. H., and R. K. Puri. 2005. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr. Purif. 39: 189-198. (Pubitemid 40084605)
30. Ostrand-Rosenberg, S., S. Baskar, N. Patterson, and V. K. Clements. 1996. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47: 414-421. (Pubitemid 26168346)
31. Liao, F., R. L. Rabin, J. R. Yannelli, L. G. Koniaris, P. Vanguri, and J. M. Farber. 1995. Human Mig chemokine: biochemical and functional characterization. J. Exp. Med. 182: 1301-1314.
32. Di Carlo, E., A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini. 2004. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547. (Pubitemid 38116798)
33. Inngjerdingen, M., B. Rolstad, and J. C. Ryan. 2003. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12. J. Immunol. 171: 2889-2895. (Pubitemid 37093509)
34. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754. (Pubitemid 28096070)
35. Shinkai, Y., G. Rathbun, K. P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. M. Stall, et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68: 855-867.
36. Nomura, T., and S. Sakaguchi. 2005. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr. Top. Microbiol. Immunol. 293: 287-302. (Pubitemid 40791234)
37. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645. (Pubitemid 40094255)
38. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by Larginine metabolism. Nat. Rev. Immunol. 5: 641-654. (Pubitemid 41113195)
39. Kawakami, K., M. Terabe, M. Kioi, J. A. Berzofsky, and R. K. Puri. 2006. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors. Clin. Cancer Res. 12: 4678-4686. (Pubitemid 44297821)
40. Kioi, M., T. Shimamura, H. Nakashima, M. Hirota, I. Tohnai, S. R. Husain, and R. K. Puri. 2009. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int. J. Cancer 124: 1440-1448.
41. Fujisawa, T., H. Nakashima, A. Nakajima, B. H. Joshi, and R. K. Puri. 2011. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int. J. Cancer 128: 1221-1231.
42. Narvaiza, I., G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, and J. Prieto. 2000. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164: 3112-3122. (Pubitemid 30148972)
43. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296. (Pubitemid 46697910)
44. Gabrilovich, D. I., M. P. Velders, E. M. Sotomayor, and W. M. Kast. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166: 5398-5406. (Pubitemid 32374159)
45. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449. (Pubitemid 36951016)
46. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702. (Pubitemid 44833345)